Table 3 Characteristics of subjects based on antibody increase after booster dose

Clinical characteristics

 Sex, n (%)

 Male

14 (50%)

6 (60%)

0.587

 Female

14 (50%)

4 (40%)

Age, years

45 (40–52.7)

53 (46.5–54)

0.104

Haemodialysis adequacy (Kt/V)

1.71 ± 0.40

1.77 ± 0,35

0.748

Laboratory characteristics

 Hemoglobin, g/dL

  Mean ± SD

9.16 ± 1.43

9.17 ± 1.42

0.991

 Lymphocyte count, 10⁹ cells/L

  Median (IQR)

1,485 (1,085–1,767.5)

1,215 (1,030–1,577.5)

 Thrombocyte count, 10⁹ cells/L

  Mean ± SD

215,392.86 ± 62,778.47

243,800.00 ± 79,333.05

0.259

 BUN, mg/dL

  Mean ± SD

59.56 ± 12.98

57.04 ± 17.40

0.634

 Creatinine, mg/dL

  Mean ± SD

12.17 ± 3.47

12.50 ± 4.12

0.804

 Ferritin, ng/mL

  Median (IQR)

390.50 (217.25–800.00)

522.00 (140.00–741.45)

0.895

 Albumin, g/dL

  Median (IQR)

4.10 (3.93–4.25)

4.00 (3.74 – 4.18)

0.246

Humoral responses

 IgG-sRBD, U/mL

  Baseline

    < 0.8 (Seronegative)

0

0

NA

    ≥ 0.8 (Seropositive)

6,231.50 (996.25–12,465.25)

22,085.50 (8,933.25–69,275.75)

0.004

28 days after booster dose

23,756.50 (12,517.50–41,339.25)

16,611.50 (7,872.50- 41,711.75)

0.507

Mean fold increase

4.23 (2.08–15.52)

0.71 (0.65–0.88)

0.000

NAbs, % inhibition

 Baseline

   < 30 (Seronegative)

0

0

NA

   ≥ 30 (Seropositive)

97.00 (89.75–97.00)

97.50 (94.75–98.00)

0.248

28 days after booster dose

97 (97–98)

96.5 (95–97.25)

0.123

Mean increase

1 (1–1.04)

1.00 (0.99–1.00)

0.041